4 analysts have expressed a variety of opinions on Ginkgo Bioworks Holdings (NYSE:DNA) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $1.8, along with a high estimate of $2.50 and a low estimate of $1.10. Marking an increase of 44.0%, the current average surpasses the previous average …